Oncology Capital Raises in the U.S. – January 16th-31st, 2025
Several interesting transactions closed in the Oncology sector over the past two weeks. If you would like more info on these deals or would like to discuss the capital raising market for your company, please contact me.
PIPE
-
- Lineage Cell Therapeutics, a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases, received $30 million of development capital from Broadwood Partners and other institutional investors, over 2 tranches through a private placement.
- Portage Biotech, engaged in researching and developing pharmaceutical and biotech products through clinical proof of concept with an initial focus on unmet clinical needs, received $2.15 million of development capital from two Portage directors through a private placement.
PE Growth/Expansion
-
- Elucent Medical, developer of a breast cancer detection system designed to eliminate the need for a metal clip, received $30 million of development capital from Trinity Capital.
Later Stage VC
-
- GT Medical Technologies, developer of a medical therapeutic device designed to overcome the limitations of current treatments by placing it after the tumor removal, raised $37 million through a combination of Series D-1 and Series D-2 venture funding in a deal led by Evidity Health Capital and Accelmed.
- Imvax, developer of patient-specific vaccines and immunotherapy strategies designed for the treatment of malignant gliomas and other cancers with unmet medical needs, raised $29 million of venture funding.
Early Stage VC
-
- MH3D, developer of nuclear imaging technology designed for medical research, raised $3.31 million of venture funding.
- Pi Health, developer of a global health technology platform designed for secure and compliant data collection during clinical trials, raised $28,725 of venture funding from BakerBridge Capital, and other investors.
Angel, Seed, and Grant
-
- Teal Health, developer of a cervical cancer screening device designed to focus on solving pressing issues in women’s health, raised $23.45 million through a combination of Seed and Seed-1 funding in a deal led by Forerunner Ventures and Emerson Collective.
- Triangulate Labs, developer of a 3-dimensional mapping technology designed to help dermatologists cure skin cancer, raised $1.62 million of seed funding in the form of SAFE notes from Lorentzen Investments and other investors.
#castleplacement #capitalraising #privateequity #venturecapital #investment #oncology
Gary Levy
Managing Director
Over 30 years in financial services, including senior roles at Citi, Ivy Asset Management (an Affiliate of BNY) and TIAA. Founder and President of Biltmore Savings Consultants, a provider of B2B technology solutions to improve operations. Author of published book "21 Ways to Improve Your Business Operations." MBA - Strategic Business Management from Hofstra University’s Frank G. Zarb School of Business. BS (with a concentration in Business, Management and Economics) from SUNY Empire State College. Series 7, 63 and 79 licenses.
- Email: glevy@castleplacement.com
- (C) (516) 457-0104
 Gary LevyManaging Director |
Please contact me if you have any questions or would like to discuss your capital raise:
Email: glevy@castleplacement.com
(C) (516) 457-0104
Send us a message:
Sources: Information on this page was derived from a variety of sources including Bloomberg, Company Websites, Crunchbase, PitchBook and other news outlets. Castle Placement™ does not warrant or guarantee this information, nor makes any representations as to the accuracy of the information. For more Risks, see CPGO Risks and Disclaimers.
